Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Slowing Down Lipolysis Significantly Enhances The Oral Absorption Of Intact Solid Lipid Nanoparticles.

Z. Yu, Wufa Fan, Luting Wang, Haisheng He, Yongjiu Lv, J. Qi, Yi Lu, W. Wu
Published 2019 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Only a limited amount of orally administered lipid nanoparticles are absorbed as intact particles due to lipolysis by lipases in the gastrointestinal tract. It is hypothesized that by counteracting lipolysis, more particles will survive gastrointestinal digestion and be absorbed as intact particles. In this study, incorporation of a lipase inhibitor orlistat (OLST), as well as polyethylene glycol (PEG) coating, is employed to slow down the lipolysis using solid lipid nanoparticles (SLNs) as model particles. To explore the in vivo behaviors of the particles, near-infrared fluorescent probes with absolute aggregation-caused quenching (ACQ) properties are used to label and track the unmodified, PEG-coated and OLST-loaded SLNs. The in vitro lipolysis study indicates very fast first-order degradation of unmodified SLNs and significantly decreased degradation of OLST-SLNs. Live imaging reveals the same trend of slowed-down lipolysis in vivo which correlates well with the in vitro lipolysis. The scanning of ex vivo gastrointestinal segments confirms the considerably prolonged residence time of OLST-SLNs, mirroring the significantly decreased lipolysis rate. The observation of fluorescence in the blood, though very weak, and in the liver speaks of the oral absorption of intact SLNs. The substantially higher hepatic levels of OLST-SLNs than unmodified SLNs should be attributed to the significantly enhanced survival rate because both particles exhibit similar cellular recognition as well as similar physicochemical properties except for the survival rate. Similarly, slowing down lipolysis also contributes to the significantly enhanced cumulative lymphatic transport of OLST-SLNs (7.56% vs. 1.27% for the unmodified SLNs). The PEG coating slows down the lipolysis rate as well but not to the degree as done by OLST. As a result, the gastrointestinal residence time of PEG-SLNs has been moderately prolonged and the hepatic levels moderately increased. The weakened cellular recognition of PEG-SLNs implies that the enhanced oral absorption is solely ascribed to the slowed-down lipolysis and enhanced mucus penetration. In conclusion, the oral absorption of intact SLNs can be significantly enhanced by slowing down lipolysis, especially by OLST, showing potential as carriers for the oral delivery of labile biomacromolecules.
This paper references
10.1002/ANIE.200461868
Conformationally restricted aza-bodipy: a highly fluorescent, stable, near-infrared-absorbing dye.
W. Zhao (2005)
10.1016/j.ijpharm.2018.02.038
Lipid-based nanosuspensions for oral delivery of peptides, a critical review.
Camille Dumont (2018)
10.1016/J.EJPS.2006.12.006
An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells.
A. des Rieux (2007)
10.1039/c7nr07736j
The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers.
N. Shrestha (2018)
10.1208/s12248-014-9672-x
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels
P. Sassene (2014)
10.1016/j.plipres.2017.07.001
Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery.
M. C. Teixeira (2017)
10.1016/j.ijpharm.2015.09.014
Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach.
V. Makwana (2015)
10.1016/j.nano.2015.06.013
Environment-responsive aza-BODIPY dyes quenching in water as potential probes to visualize the in vivo fate of lipid-based nanocarriers.
X. Hu (2015)
10.2165/00003495-200666120-00012
Orlistat: a review of its use in the management of obesity.
Sheridan Henness (2006)
10.1016/S0939-6411(97)00096-9
Lectins and bacterial invasion factors for controlling endo- and transcytosis of bioadhesive drug carrier systems☆
E. Haltner (1997)
10.1016/j.jconrel.2018.08.032
Oral peptide delivery: Translational challenges due to physiological effects
Puneet Tyagi (2018)
10.1016/J.VASCN.2003.11.004
A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: Cannulation of the mesenteric and thoracic lymph ducts within the rat.
M. Boyd (2004)
10.1016/j.ijpharm.2018.02.045
Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system
Elodie Czuba (2018)
10.1248/CPB.55.251
HPLC analysis of orlistat and its application to drug quality control studies.
E. Souri (2007)
10.1016/j.nano.2011.08.016
Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
Zhiwen Zhang (2012)
10.1016/S1773-2247(13)50054-2
Recent developments in oral lipid-based drug delivery
Nicky Thomas (2013)
10.1211/0022357021771896
Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products
L. Sek (2002)
10.1016/S0163-7827(03)00050-X
The digestion of dietary triacylglycerols.
Huiling Mu (2004)
10.1016/j.drudis.2014.04.011
Is nanotechnology a boon for oral drug delivery?
Udita Agrawal (2014)
10.1007/s11095-014-1532-y
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase
Jean-Claude Bakala-N’Goma (2014)
10.1021/acs.molpharmaceut.7b00742
Size Effect on Lipid Nanocapsule-Mediated GLP-1 Secretion from Enteroendocrine L Cells.
Yining Xu (2018)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/j.ijpharm.2018.03.048
Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice
L. C. G. A. I. Moreno (2018)
10.1016/j.jcis.2015.10.057
Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery.
Ana Rute Neves (2016)
10.2478/acph-2013-0040
Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs
Katja Čerpnjak (2013)
10.1039/C8NH00010G
Reassessment of long circulation via monitoring of integral polymeric nanoparticles justifies a more accurate understanding.
Haisheng He (2018)
10.1023/A:1011975120776
Solid Lipid Nanoparticles in Lymph and Plasma After Duodenal Administration to Rats
A. Bargoni (2004)
10.1016/j.jconrel.2017.07.045
Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs.
Lei Wu (2017)
10.1016/j.jconrel.2017.11.046
Epithelia transmembrane transport of orally administered ultrafine drug particles evidenced by environment sensitive fluorophores in cellular and animal studies
Yike Xie (2018)
10.1016/j.nano.2017.07.014
In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability.
Y. Ma (2017)
10.1016/j.addr.2019.05.009
Towards more accurate bioimaging of drug nanocarriers: turning aggregation-caused quenching into a useful tool.
J. Qi (2019)
10.1016/j.drudis.2016.09.024
In vivo fate of lipid-based nanoparticles.
J. Qi (2017)
10.1038/nrd2197
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
C. H. Porter (2007)
10.1208/s12249-018-1188-8
Lipid-Based Oral Formulation Strategies for Lipophilic Drugs
Vivek Patel (2018)
10.1016/J.EJPS.2004.12.006
Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs.
A. Dahan (2005)
10.1002/mnfr.201000381
Absorption and metabolism of the mycotoxin zearalenone and the growth promotor zeranol in Caco-2 cells in vitro.
E. Pfeiffer (2011)
10.2217/nnm.12.141
Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle-double emulsion method via the combined use of different solid lipids.
Chunhui Chen (2013)
10.1016/j.jconrel.2011.03.033
Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration.
T. Nguyen (2011)
10.1208/s12249-018-0986-3
Lyotropic Liquid Crystalline Nanoparticles of Amphotericin B: Implication of Phytantriol and Glyceryl Monooleate on Bioavailability Enhancement
S. Jain (2018)
10.1016/j.jconrel.2016.06.016
Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.
A. Date (2016)
10.1016/j.apsb.2018.06.005
Adapting liposomes for oral drug delivery
Haisheng He (2019)
10.1021/acsami.8b00507
Novel Solid Lipid Nanoparticle with Endosomal Escape Function for Oral Delivery of Insulin.
Yining Xu (2018)
10.1021/acsami.7b04916
Size-Dependent Translocation of Nanoemulsions via Oral Delivery.
F. Xia (2017)
10.1007/s11095-012-0961-8
Ternary Polymeric Nanoparticles for Oral siRNA Delivery
J. Zhang (2012)
10.1016/j.jconrel.2014.07.037
'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
O. Feeney (2014)
10.1021/mp300649z
Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
H. Yuan (2013)
10.1016/j.jconrel.2012.12.021
Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
A. Beloqui (2013)
10.1039/c5nr07474f
Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery.
Xiongwei Hu (2016)
10.1016/j.jconrel.2018.01.009
Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small
P. Tyagi (2018)
10.1039/c6nr07581a
Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles.
E. Ahmad (2017)
10.1038/nrd.2018.183
Non-invasive delivery strategies for biologics
Aaron C. Anselmo (2019)
10.1016/j.apsb.2018.07.004
Exploring the utility of the Chasing Principle: influence of drug-free SNEDDS composition on solubilization of carvedilol, cinnarizine and R3040 in aqueous suspension
ScheylaDaniela Siqueira Jørgensen (2019)
10.1021/ACS.MOLPHARMACEUT.6B00705
Bioimaging of Intravenous Polymeric Micelles Based on Discrimination of Integral Particles Using an Environment-Responsive Probe.
Haisheng He (2016)
10.1021/JS960110X
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans.
E. Walter (1996)
10.1016/j.ejps.2011.04.011
Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats.
M. Sun (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar